イソ吉草酸血症（IVA）治療の世界市場レポート (2025年)

イソ吉草酸血症（IVA）治療の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.8％で7億9,000万米ドルに成長します。予測期間を見ると、IVA治療の成長は、遺伝子治療アプローチの採用の増加、希少疾患研究への投資の増加、新規治療オプションのパイプラインの増加、バイオテクノロジー企業と研究機関の共同研究の増加によって牽引されると予想されます。また、特にIVAなどの代謝性疾患では、個別化医療が重視されるようになってきています。IVA治療の将来を形成すると思われる主な動向には、遺伝子検査技術の進歩、代謝治療薬の革新的ドラッグデリバリーシステム、酵素補充製剤の改良、標的遺伝子編集ツールの開発、新生児スクリーニング手法の進歩などがあります。これらの動向は、治療効果を向上させ、より利用しやすくする可能性を秘めており、IVA患者の管理と転帰の改善に希望を与えるものです。

代謝性疾患の有病率の増加は、イソ吉草酸血症（IVA）治療市場の成長を促進すると予想されます。糖尿病、甲状腺機能低下症、甲状腺機能亢進症、イソ吉草酸血症（IVA）などの代謝障害は、正常な代謝プロセスを乱し、体内で食物をエネルギーに変換する方法に影響を与えます。これらの疾患の有病率は、主に食生活の乱れや運動不足などの生活習慣に関連した要因によって上昇し、肥満やインスリン抵抗性などの状態を引き起こしています。イソ吉草酸血症の治療は、体内に蓄積された有害物質に対処し、正常な代謝機能の回復を助け、神経障害などの合併症を予防します。例えば、米国糖尿病協会によると、米国では2022年に約2,550万人が糖尿病と診断され、人口の7.6％を占める。このような代謝異常の有病率の増加が、IVA治療市場の成長を牽引しています。

希少遺伝性疾患に対する認識の高まりも、IVA治療市場の成長を促進すると予想されます。遺伝子の変異によって引き起こされる希少遺伝性疾患は、多くの場合、少数の個人を罹患させますが、診断技術や遺伝子スクリーニング・プログラムの進歩により、目に見える形になってきています。これらの改善により、より早期かつ正確な発見が可能となり、これらの疾患のより良い管理につながっています。イソ吉草酸血症の治療では、このまれな遺伝性疾患に特化し、特殊な栄養レジメン、アミノ酸補助食品、時には薬物療法を行うことで、毒性代謝産物の蓄積を抑え、代謝性クリーゼを予防します。2023年2月、世界保健機関（WHO）は、心疾患や神経管欠損症などの出生異常が年間数千人の死亡の原因になっていると報告しました。さらに、レディ小児病院で実施された調査では、乳児死亡の41％が単遺伝子（メンデル）疾患によるものであることが明らかになりました。これらの調査結果は、希少遺伝性疾患に対する認識を高め、診断を改善することの重要性を強調するものであり、IVA治療市場の成長をさらに後押しするものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場のマクロ経済シナリオ：金利・インフレ・地政学・貿易戦争・関税・コロナ禍と回復が市場に及ぼす影響を含む

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のイソ吉草酸血症（IVA）治療市場：PESTEL分析（政治・社会・技術・環境・法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のイソ吉草酸血症（IVA）治療市場：成長率分析
• 世界のイソ吉草酸血症（IVA）治療の市場規模・成長率：実績値、2019～2024年
• 世界のイソ吉草酸血症（IVA）治療の市場規模・成長率：予測値、2024～2029年、2034年
• 世界のイソ吉草酸血症（IVA）治療市場：総有効市場（TAM）

第6章 市場セグメンテーション

• 世界のイソ吉草酸血症（IVA）治療市場：種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 古典的イソ吉草酸血症
• 中等度イソ吉草酸血症
• 非古典的イソ吉草酸血症
• 世界のイソ吉草酸血症（IVA）治療市場：治療法別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 食事管理
• 酵素補充療法
• 遺伝子治療
• 薬物治療
• 世界のイソ吉草酸血症（IVA）治療市場：投与経路別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 経口剤
• 注射剤
• 世界のイソ吉草酸血症（IVA）治療市場：エンドユーザー別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• 在宅医療
• 世界のイソ吉草酸血症（IVA）治療市場（古典的イソ吉草酸血症）：種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 食事管理
• カルニチンサプリメント
• グリシンサプリメント
• 緊急管理
• 遺伝子治療（治験）
• 世界のイソ吉草酸血症（IVA）治療市場（非古典的イソ吉草酸血症）：種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 観察と予防ケア
• 軽度の食生活の変更
• 時々の補給
• 遺伝カウンセリングとモニタリング
• 世界のイソ吉草酸血症（IVA）治療市場（中等度イソ吉草酸血症）：種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• タンパク質制限食
• 間欠的カルニチン/グリシン療法
• 定期的なモニタリングと支持療法
• 急性発作管理

第7章 地域別・国別の分析

• 世界のイソ吉草酸血症（IVA）治療市場：地域別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 世界のイソ吉草酸血症（IVA）治療市場：国別、実績値・予測値、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• イソ吉草酸血症（IVA）治療市場：競合情勢
• イソ吉草酸血症（IVA）治療市場：企業プロファイル
  • Nestle Health Science S.A.（概要、製品・サービス、戦略、財務分析）
  • BioMarin Pharmaceutical Inc.（概要、製品・サービス、戦略、財務分析）
  • GenScript Biotech Corporation（概要、製品・サービス、戦略、財務分析）
  • Nutricia Advanced Medical Nutrition（概要、製品・サービス、戦略、財務分析）
  • Rocket Pharmaceuticals Inc.（概要、製品・サービス、戦略、財務分析）

第31章 その他の大手企業と革新的企業

• REGENXBIO Inc.
• uniQure N.V.
• Vitaflo International Ltd.
• Orchard Therapeutics plc
• Editas Medicine Inc.
• Cambrooke Therapeutics Inc.
• Recordati Rare Diseases Inc.
• Abbott Nutrition
• Targeted Medical Pharma Inc.
• Solace Nutrition LLC
• Nutricia Metabolics
• Bluebird Bio Inc.
• Verve Therapeutics Inc.
• Abeona Therapeutics Inc.
• CRISPR Therapeutics AG

第32章 世界市場：競合ベンチマーキング・ダッシュボード

第33章 主要な企業合併・買収 (M&A)

第34章 最近の市場動向

第35章 市場の潜在力の高い国・部門と戦略

• イソ吉草酸血症（IVA）治療市場：最新機会を提供する国（2029年）
• イソ吉草酸血症（IVA）治療市場：最新機会を提供する部門（2029年）
• イソ吉草酸血症（IVA）治療市場：成長戦略（2029年）
  • 市場動向に基づく戦略
  • 競争戦略

第36章 付録

Isovaleric acidemia (IVA) treatment involves managing a rare inherited metabolic disorder caused by a deficiency in the enzyme isovaleryl-CoA dehydrogenase, resulting in the buildup of isovaleric acid in the body. The goal of treatment is to decrease the accumulation of toxic substances and prevent metabolic crises.

The primary types of IVA treatment are classical isovaleric acidemia, moderate isovaleric acidemia, and non-classical isovaleric acidemia. Classical IVA is a severe metabolic disorder caused by the deficiency of isovaleryl-CoA dehydrogenase, which plays a crucial role in metabolizing the amino acid leucine. Treatments for IVA include dietary management, enzyme replacement therapy, gene therapy, and pharmacological interventions. These treatments are administered either orally or through injections and are provided in various settings, such as hospitals, clinics, and home care environments.

The isovaleric acidemia (IVA) treatment market research report is one of a series of new reports from The Business Research Company that provides isovaleric acidemia (IVA) treatment market statistics, including the isovaleric acidemia (IVA) treatment industry global market size, regional shares, competitors with the isovaleric acidemia (IVA) treatment market share, detailed isovaleric acidemia (IVA) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the isovaleric acidemia (IVA) treatment industry. This isovaleric acidemia (IVA) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The isovaleric acidemia (IVA) treatment market size has grown strongly in recent years. It will grow from $0.60 billion in 2024 to $0.63 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period of isovaleric acidemia (IVA) treatment can be attributed to awareness of rare metabolic disorders, expansion of newborn screening programs aiding early diagnosis, growing government funding for orphan diseases, focus on enzyme replacement therapies, and rising demand for early diagnosis and genetic counseling. These efforts have improved IVA detection and management, leading to better patient outcomes.

The isovaleric acidemia (IVA) treatment market size is expected to see strong growth in the next few years. It will grow to $0.79 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. Looking to the forecast period, the growth of IVA treatment is expected to be driven by the increasing adoption of gene therapy approaches, rising investments in rare disease research, a growing pipeline of novel treatment options, and more collaborations between biotech firms and research institutions. There's also a rising emphasis on personalized medicine, particularly for metabolic disorders such as IVA. Major trends that are likely to shape the future of IVA treatment include advancements in genetic testing technologies, innovative drug delivery systems for metabolic therapies, improvements in enzyme replacement formulations, the development of targeted gene editing tools, and progress in newborn screening methodologies. These trends have the potential to improve the effectiveness of treatments and make them more accessible, offering hope for better management and outcomes for patients with IVA.

The increasing prevalence of metabolic disorders is expected to propel the growth of the isovaleric acidemia (IVA) treatment market. Metabolic disorders, such as diabetes mellitus, hypothyroidism, hyperthyroidism, and isovaleric acidemia (IVA), disrupt normal metabolic processes and affect how the body converts food into energy. The prevalence of these disorders is rising, primarily due to lifestyle-related factors such as poor diet and physical inactivity, leading to conditions such as obesity and insulin resistance. Isovaleric acidemia treatment addresses the buildup of toxic substances in the body, helping to restore normal metabolic function and preventing complications such as neurological damage. For example, according to the American Diabetes Association, approximately 25.5 million people in the U.S. were diagnosed with diabetes in 2022, accounting for 7.6% of the population. This increasing prevalence of metabolic disorders is driving the growth of the IVA treatment market.

The growing awareness of rare genetic disorders is also expected to propel the growth of the IVA treatment market. Rare genetic disorders, caused by mutations in genes, often affect a small number of individuals but are becoming more visible due to advancements in diagnostic technologies and genetic screening programs. These improvements allow for earlier and more accurate detection, leading to better management of these conditions. Isovaleric acidemia treatment specifically addresses this rare genetic disorder by offering specialized dietary regimens, amino acid supplementation, and sometimes medications to reduce the buildup of toxic metabolites and prevent metabolic crises. In February 2023, the World Health Organization reported that birth abnormalities, including conditions such as heart defects and neural tube defects, contribute to thousands of deaths annually. Additionally, a study conducted at Rady Children's Hospital revealed that 41% of infant deaths were due to single-locus (Mendelian) genetic diseases. These findings underscore the importance of raising awareness and improving diagnosis for rare genetic disorders, further fueling the growth of the IVA treatment market.

The rising adoption of personalized medicine is also driving the growth of the IVA treatment market. Personalized medicine, which tailors treatment based on individual characteristics such as genetics, lifestyle, and environment, is increasingly prevalent due to advancements in genetic testing and biomarker research. In the case of isovaleric acidemia, personalized medicine involves utilizing genetic insights to customize dietary and pharmacological interventions based on an individual's metabolic profile. This approach enhances treatment outcomes and reduces complications. For instance, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from 6 in 2022, according to the Personalized Medicine Coalition. As personalized healthcare continues to evolve, the growth of the IVA treatment market is expected to accelerate, driven by the need for tailored therapies that improve patient outcomes.

Major players in the isovaleric acidemia (iva) treatment market are Nestle Health Science S.A., BioMarin Pharmaceutical Inc., GenScript Biotech Corporation, Nutricia Advanced Medical Nutrition, Rocket Pharmaceuticals Inc., REGENXBIO Inc., uniQure N.V., Vitaflo International Ltd., Orchard Therapeutics plc, Editas Medicine Inc., Cambrooke Therapeutics Inc., Recordati Rare Diseases Inc., Abbott Nutrition, Targeted Medical Pharma Inc., Solace Nutrition LLC, Nutricia Metabolics, Bluebird Bio Inc., Verve Therapeutics Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG.

North America was the largest region in the isovaleric acidemia (IVA) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in isovaleric acidemia (IVA) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the isovaleric acidemia (IVA) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The isovaleric acidemia (IVA) treatment market consists of revenues earned by entities by providing services such as newborn screening programs, monitoring, and genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The isovaleric acidemia (IVA) treatment market includes sales of anticatabolic agents, L-carnitine supplements, and amino acid supplements. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Isovaleric Acidemia (IVA) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on isovaleric acidemia (iva) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for isovaleric acidemia (iva) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The isovaleric acidemia (iva) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Classical Isovaleric Acidemia; Moderate Isovaleric Acidemia; Non-classical Isovaleric Acidemia
• 2) By Treatment: Dietary Management; Enzyme Replacement Therapy; Gene Therapy; Pharmacological Treatment
• 3) By Route of Administration: Oral; Injectable
• 4)By End-user: Hospitals; Clinics; Homecare Settings
• Subsegments:
• 1) By Classical Isovaleric Acidemia: Dietary Management; Carnitine Supplementation; Glycine Supplementation; Emergency Management; Gene Therapy (Investigational)
• 2) By Non-classical Isovaleric Acidemia: Observation and Preventive Care; Mild Dietary Modifications; Occasional Supplementation; Genetic Counseling and Monitoring
• 3) By Moderate Isovaleric Acidemia: Protein-restricted Diet; Intermittent Carnitine/Glycine Therapy; Periodic Monitoring and Supportive Care; Acute Episode Management
• Companies Mentioned: Nestle Health Science S.A.; BioMarin Pharmaceutical Inc.; GenScript Biotech Corporation; Nutricia Advanced Medical Nutrition; Rocket Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Isovaleric Acidemia (IVA) Treatment Market Characteristics

3. Isovaleric Acidemia (IVA) Treatment Market Trends And Strategies

4. Isovaleric Acidemia (IVA) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Isovaleric Acidemia (IVA) Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Isovaleric Acidemia (IVA) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Isovaleric Acidemia (IVA) Treatment Market Growth Rate Analysis
• 5.4. Global Isovaleric Acidemia (IVA) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Isovaleric Acidemia (IVA) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Isovaleric Acidemia (IVA) Treatment Total Addressable Market (TAM)

6. Isovaleric Acidemia (IVA) Treatment Market Segmentation

• 6.1. Global Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Classical Isovaleric Acidemia
• Moderate Isovaleric Acidemia
• Non-classical Isovaleric Acidemia
• 6.2. Global Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dietary Management
• Enzyme Replacement Therapy
• Gene Therapy
• Pharmacological Treatment
• 6.3. Global Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• 6.4. Global Isovaleric Acidemia (IVA) Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Homecare Settings
• 6.5. Global Isovaleric Acidemia (IVA) Treatment Market, Sub-Segmentation Of Classical Isovaleric Acidemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dietary Management
• Carnitine Supplementation
• Glycine Supplementation
• Emergency Management
• Gene Therapy (Investigational)
• 6.6. Global Isovaleric Acidemia (IVA) Treatment Market, Sub-Segmentation Of Non-classical Isovaleric Acidemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Observation and Preventive Care
• Mild Dietary Modifications
• Occasional Supplementation
• Genetic Counseling and Monitoring
• 6.7. Global Isovaleric Acidemia (IVA) Treatment Market, Sub-Segmentation Of Moderate Isovaleric Acidemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Protein-restricted Diet
• Intermittent Carnitine/Glycine Therapy
• Periodic Monitoring and Supportive Care
• Acute Episode Management

7. Isovaleric Acidemia (IVA) Treatment Market Regional And Country Analysis

• 7.1. Global Isovaleric Acidemia (IVA) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Isovaleric Acidemia (IVA) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Isovaleric Acidemia (IVA) Treatment Market

• 8.1. Asia-Pacific Isovaleric Acidemia (IVA) Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Isovaleric Acidemia (IVA) Treatment Market

• 9.1. China Isovaleric Acidemia (IVA) Treatment Market Overview
• 9.2. China Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Isovaleric Acidemia (IVA) Treatment Market

• 10.1. India Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Isovaleric Acidemia (IVA) Treatment Market

• 11.1. Japan Isovaleric Acidemia (IVA) Treatment Market Overview
• 11.2. Japan Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Isovaleric Acidemia (IVA) Treatment Market

• 12.1. Australia Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Isovaleric Acidemia (IVA) Treatment Market

• 13.1. Indonesia Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Isovaleric Acidemia (IVA) Treatment Market

• 14.1. South Korea Isovaleric Acidemia (IVA) Treatment Market Overview
• 14.2. South Korea Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Isovaleric Acidemia (IVA) Treatment Market

• 15.1. Western Europe Isovaleric Acidemia (IVA) Treatment Market Overview
• 15.2. Western Europe Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Isovaleric Acidemia (IVA) Treatment Market

• 16.1. UK Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Isovaleric Acidemia (IVA) Treatment Market

• 17.1. Germany Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Isovaleric Acidemia (IVA) Treatment Market

• 18.1. France Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Isovaleric Acidemia (IVA) Treatment Market

• 19.1. Italy Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Isovaleric Acidemia (IVA) Treatment Market

• 20.1. Spain Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Isovaleric Acidemia (IVA) Treatment Market

• 21.1. Eastern Europe Isovaleric Acidemia (IVA) Treatment Market Overview
• 21.2. Eastern Europe Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Isovaleric Acidemia (IVA) Treatment Market

• 22.1. Russia Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Isovaleric Acidemia (IVA) Treatment Market

• 23.1. North America Isovaleric Acidemia (IVA) Treatment Market Overview
• 23.2. North America Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Isovaleric Acidemia (IVA) Treatment Market

• 24.1. USA Isovaleric Acidemia (IVA) Treatment Market Overview
• 24.2. USA Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Isovaleric Acidemia (IVA) Treatment Market

• 25.1. Canada Isovaleric Acidemia (IVA) Treatment Market Overview
• 25.2. Canada Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Isovaleric Acidemia (IVA) Treatment Market

• 26.1. South America Isovaleric Acidemia (IVA) Treatment Market Overview
• 26.2. South America Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Isovaleric Acidemia (IVA) Treatment Market

• 27.1. Brazil Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Isovaleric Acidemia (IVA) Treatment Market

• 28.1. Middle East Isovaleric Acidemia (IVA) Treatment Market Overview
• 28.2. Middle East Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Isovaleric Acidemia (IVA) Treatment Market

• 29.1. Africa Isovaleric Acidemia (IVA) Treatment Market Overview
• 29.2. Africa Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Isovaleric Acidemia (IVA) Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Isovaleric Acidemia (IVA) Treatment Market Competitive Landscape And Company Profiles

• 30.1. Isovaleric Acidemia (IVA) Treatment Market Competitive Landscape
• 30.2. Isovaleric Acidemia (IVA) Treatment Market Company Profiles
  • 30.2.1. Nestle Health Science S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. BioMarin Pharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. GenScript Biotech Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Nutricia Advanced Medical Nutrition Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Rocket Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Isovaleric Acidemia (IVA) Treatment Market Other Major And Innovative Companies

• 31.1. REGENXBIO Inc.
• 31.2. uniQure N.V.
• 31.3. Vitaflo International Ltd.
• 31.4. Orchard Therapeutics plc
• 31.5. Editas Medicine Inc.
• 31.6. Cambrooke Therapeutics Inc.
• 31.7. Recordati Rare Diseases Inc.
• 31.8. Abbott Nutrition
• 31.9. Targeted Medical Pharma Inc.
• 31.10. Solace Nutrition LLC
• 31.11. Nutricia Metabolics
• 31.12. Bluebird Bio Inc.
• 31.13. Verve Therapeutics Inc.
• 31.14. Abeona Therapeutics Inc.
• 31.15. CRISPR Therapeutics AG

32. Global Isovaleric Acidemia (IVA) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Isovaleric Acidemia (IVA) Treatment Market

34. Recent Developments In The Isovaleric Acidemia (IVA) Treatment Market

35. Isovaleric Acidemia (IVA) Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Isovaleric Acidemia (IVA) Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Isovaleric Acidemia (IVA) Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Isovaleric Acidemia (IVA) Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer